1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Chemotherapy Effects – Pipeline Review, H1 2013

Chemotherapy Effects – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 302 pages

Chemotherapy Effects – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Chemotherapy Effects - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Effects, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Effects. Chemotherapy Effects - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Effects.
- A review of the Chemotherapy Effects products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Effects pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Effects.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Effects pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Chemotherapy Effects - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Chemotherapy Effects Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Chemotherapy Effects 13
Chemotherapy Effects Therapeutics under Development by Companies 15
Chemotherapy Effects Therapeutics under Investigation by Universities/Institutes 22
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Chemotherapy Effects Therapeutics - Products under Development by Companies 28
Chemotherapy Effects Therapeutics - Products under Investigation by Universities/Institutes 35
Companies Involved in Chemotherapy Effects Therapeutics Development 36
Kyowa Hakko Kirin Co., Ltd. 36
Amgen Inc. 37
Adherex Technologies Inc. 38
Eli Lilly and Company 39
BioDelivery Sciences International, Inc. 40
Merck and Co., Inc. 41
Lentigen Corporation 42
Reliance Life Sciences Pvt. Ltd. 43
A.P. Pharma, Inc. 44
Aphios Corporation 45
Axcan Pharma Inc. 46
Dong-A Pharmaceutical Co., Ltd. 47
Dr. Reddy's Laboratories Limited 48
Maxygen, Inc. 49
Sigma-Tau S.p.A. 50
Teva Pharmaceutical Industries Limited 51
Sandoz Inc. 52
CEL-SCI Corporation 53
Zosano Pharma, Inc. 54
3SBio Inc. 55
EpiCept Corporation 56
Hana Biosciences, Inc. 57
IntelGenx Technologies Corp. 58
NovaDel Pharma, Inc. 59
La Jolla Pharmaceutical Company 60
Telik, Inc. 61
Mundipharma International Limited 62
Cerbios-Pharma SA 63
ProMetic Life Sciences Inc. 64
Lipoxen PLC 65
LG Life Sciences, Ltd 66
Diamyd Medical AB 67
Pluristem Therapeutics Inc. 68
DARA BioSciences, Inc. 69
LTT Bio-Pharma Co., Ltd. 70
Uni-Bio Science Group Ltd. 71
ProStrakan Group plc 72
Teikoku Pharma USA, Inc. 73
SymBio Pharmaceuticals Limited 74
Cellerant Therapeutics, Inc. 75
Spectrum Pharmaceuticals, Inc. 76
INSYS Therapeutics, Inc. 77
Pharmagenesis, Inc. 78
Neurotune AG 79
Med Discovery SA 80
Helsinn Healthcare S.A. 81
Wellstat Therapeutics Corporation 82
Ventria Bioscience 83
PledPharma AB 84
Tranzyme Pharma, Inc. 85
Indus Biotech Private Limited 86
Synageva BioPharma Corp. 87
Phage Biotechnology Corporation 88
Inimex Pharmaceuticals, Inc. 89
Bolder Biotechnology, Inc. 90
Shin Nippon Biomedical Laboratories, Ltd. 91
Welichem Biotech Inc. 92
Sound Pharmaceuticals, Inc. 93
SpePharm Holding B.V. 94
Biothera 95
Avesthagen Limited 96
Spinifex Pharmaceuticals Pty Limited 97
Tosk, Inc. 98
Almac Discovery Ltd. 99
Pfenex Inc. 100
Mycenax Biotech Inc. 101
Therapure Biopharma Inc. 102
Eurofarma 103
Neumedicines Inc. 104
Applied Protein Sciences, LLC 105
Acacia Pharma Ltd. 106
Advancell 107
Chemotherapy Effects - Therapeutics Assessment 108
Assessment by Monotherapy Products 108
Assessment by Combination Products 109
Assessment by Route of Administration 110
Assessment by Molecule Type 112
Drug Profiles 115
Romiplostim - Drug Profile 115
rolapitant hydrochloride - Drug Profile 117
MAXY-G34 - Drug Profile 118
sodium thiosulfate - Drug Profile 120
menadione - Drug Profile 122
ondansetron MR - Drug Profile 123
granisetron - Drug Profile 124
MDPK-67b - Drug Profile 125
NT-13317 - Drug Profile 127
ondansetron hydrochloride - Drug Profile 128
Multikine - Drug Profile 129
TZP-201 - Drug Profile 131
dronabinol - Drug Profile 132
Slow-Release G-CSF - Drug Profile 133
KRN-5500 - Drug Profile 134
NuPIAO - Drug Profile 136
granisetron - Drug Profile 137
granisetron - Drug Profile 138
(amitriptyline + ketamine) - Drug Profile 140
ondansetron CR - Drug Profile 141
ezatiostat hydrochloride - Drug Profile 142
Pegylated GCSF - Drug Profile 144
LG-631 - Drug Profile 145
filgrastim - Drug Profile 147
ZP-1846 - Drug Profile 148
PBI-1402 - Drug Profile 149
balugrastim - Drug Profile 150
INDUS-82020 - Drug Profile 152
leteprinim - Drug Profile 153
PHY-626 - Drug Profile 154
PHY-777 - Drug Profile 155
ErepoXen - Drug Profile 156
IMX-942 - Drug Profile 157
GCS-100 - Drug Profile 158
CLT-008 - Drug Profile 160
GranNEX - Drug Profile 161
granisetron - Drug Profile 162
Dexamethasone + Granisetron + Prochlorperazine - Drug Profile 163
F-511 cream - Drug Profile 165
filgrastim - Drug Profile 166
pegfilgrastim - Drug Profile 167
levocarnitine - Drug Profile 168
buprenorphine hydrochloride - Drug Profile 169
pegfilgrastim - Drug Profile 170
MTP-131 - Drug Profile 171
lipegfilgrastim - Drug Profile 173
darbepoetin alfa - Drug Profile 174
LY-2787106 - Drug Profile 175
dexrazoxane - Drug Profile 176
palonosetron hydrochloride - Drug Profile 177
ATH-008 - Drug Profile 178
droperidol - Drug Profile 179
CR-3294 - Drug Profile 180
uridine triacetate - Drug Profile 181
TPW-146 - Drug Profile 183
EMA-401 - Drug Profile 184
SPI-1005 - Drug Profile 186
ebselen - Drug Profile 188
granisetron - Drug Profile 189
WBI-2100 + [cisplatin] - Drug Profile 190
WBI-2100 + [gemcitabine hydrochloride] - Drug Profile 191
WBI-2100 + [dacarbazine] - Drug Profile 192
WBI-2100 + [paclitaxel] - Drug Profile 193
(netupitant + palonosetron hydrochloride) - Drug Profile 194
NMIL12-1 - Drug Profile 196
dexamethasone acetate + [palonosetron hydrochloride] - Drug Profile 198
PanCyte - Drug Profile 199
erythropoietin biosimilar - Drug Profile 200
APD-403 - Drug Profile 201
NT-24336 - Drug Profile 202
UNI-rhIL-11 - Drug Profile 203
TBI-304 - Drug Profile 204
BBT-015 - Drug Profile 205
BBT-018 - Drug Profile 206
IRX-4310 - Drug Profile 207
Imprime PGG - Drug Profile 208
5HT3 receptor antagonist + [dexamethasone ] + [fosaprepitant dimeglumine] - Drug Profile 210
filgrastim - Drug Profile 211
aprepitant - Drug Profile 212
granisetron - Drug Profile 213
filgrastim - Drug Profile 215
darbepoetin alfa - Drug Profile 216
budesonide - Drug Profile 217
Plasmid Gene Therapy For Chemotherapy-Induced Thrombocytopenia - Drug Profile 218
carbamazepine - Drug Profile 219
Filgrastim Biosimilar - Drug Profile 220
F-627 - Drug Profile 221
palonosetron hydrochloride New Formulation - Drug Profile 222
dronabinol Intavenous - Drug Profile 223
PLX-BMP - Drug Profile 224
calcitriol - Drug Profile 227
INT-0010 - Drug Profile 228
PLED-mangafodipir trisodium - Drug Profile 229
NN1 Neurotrophin - Drug Profile 231
erythromycin - Drug Profile 232
AK-295 - Drug Profile 233
NecroX-7 - Drug Profile 234
amisulpride - Drug Profile 235
VEN-101 - Drug Profile 236
TK-112690 - Drug Profile 237
filgrastim Biosimilar - Drug Profile 238
pegfilgrastim Biosimilar - Drug Profile 239
AP-002 - Drug Profile 240
Prostaglandin E2 - Drug Profile 241
TheraPhil - Drug Profile 242
PG2-2000 - Drug Profile 243
granisetron - Drug Profile 244
SHIP1 Inhibitors - Drug Profile 245
Apoptosis Inhibitors - Drug Profile 246
Chemotherapy Effects Therapeutics - Drug Profile Updates 247
Chemotherapy Effects Therapeutics - Discontinued Products 283
Chemotherapy Effects Therapeutics - Dormant Products 284
Chemotherapy Effects - Product Development Milestones 288
Featured News and Press Releases 288
Appendix 294
Methodology 294
Coverage 294
Secondary Research 294
Primary Research 294
Expert Panel Validation 294
Contact Us 295
Disclaimer 295



List of Tables

Number of Products Under Development for Chemotherapy Effects, H1 2013 20
Products under Development for Chemotherapy Effects - Comparative Analysis, H1 2013 21
Number of Products under Development by Companies, H1 2013 23
Number of Products under Development by Companies, H1 2013 (Contd..1) 24
Number of Products under Development by Companies, H1 2013 (Contd..2) 25
Number of Products under Development by Companies, H1 2013 (Contd..3) 26
Number of Products under Development by Companies, H1 2013 (Contd..4) 27
Number of Products under Development by Companies, H1 2013 (Contd..5) 28
Number of Products under Investigation by Universities/Institutes, H1 2013 30
Comparative Analysis by Late Stage Development, H1 2013 31
Comparative Analysis by Mid Clinical Stage Development, H1 2013 32
Comparative Analysis by Early Clinical Stage Development, H1 2013 33
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 34
Products under Development by Companies, H1 2013 35
Products under Development by Companies, H1 2013 (Contd..1) 36
Products under Development by Companies, H1 2013 (Contd..2) 37
Products under Development by Companies, H1 2013 (Contd..3) 38
Products under Development by Companies, H1 2013 (Contd..4) 39
Products under Development by Companies, H1 2013 (Contd..5) 40
Products under Development by Companies, H1 2013 (Contd..6) 41
Products under Investigation by Universities/Institutes, H1 2013 42
Kyowa Hakko Kirin Co., Ltd., H1 2013 43
Amgen Inc., H1 2013 44
Adherex Technologies Inc., H1 2013 45
Eli Lilly and Company, H1 2013 46
BioDelivery Sciences International, Inc., H1 2013 47
Merck and Co., Inc., H1 2013 48
Lentigen Corporation, H1 2013 49
Reliance Life Sciences Pvt. Ltd., H1 2013 50
A.P. Pharma, Inc., H1 2013 51
Aphios Corporation, H1 2013 52
Axcan Pharma Inc., H1 2013 53
Dong-A Pharmaceutical Co., Ltd., H1 2013 54
Dr. Reddy's Laboratories Limited, H1 2013 55
Maxygen, Inc., H1 2013 56
Sigma-Tau S.p.A., H1 2013 57
Teva Pharmaceutical Industries Limited, H1 2013 58
Sandoz Inc., H1 2013 59
CEL-SCI Corporation, H1 2013 60
Zosano Pharma, Inc., H1 2013 61
3SBio Inc., H1 2013 62
EpiCept Corporation, H1 2013 63
Hana Biosciences, Inc., H1 2013 64
IntelGenx Technologies Corp., H1 2013 65
NovaDel Pharma, Inc., H1 2013 66
La Jolla Pharmaceutical Company, H1 2013 67
Telik, Inc., H1 2013 68
Mundipharma International Limited, H1 2013 69
Cerbios-Pharma SA, H1 2013 70
ProMetic Life Sciences Inc., H1 2013 71
Lipoxen PLC, H1 2013 72
LG Life Sciences, Ltd, H1 2013 73
Diamyd Medical AB, H1 2013 74
Pluristem Therapeutics Inc., H1 2013 75
DARA BioSciences, Inc., H1 2013 76
LTT Bio-Pharma Co., Ltd., H1 2013 77
Uni-Bio Science Group Ltd., H1 2013 78
ProStrakan Group plc, H1 2013 79
Teikoku Pharma USA, Inc., H1 2013 80
SymBio Pharmaceuticals Limited, H1 2013 81
Cellerant Therapeutics, Inc., H1 2013 82
Spectrum Pharmaceuticals, Inc., H1 2013 83
INSYS Therapeutics, Inc., H1 2013 84
Pharmagenesis, Inc., H1 2013 85
Neurotune AG, H1 2013 86
Med Discovery SA, H1 2013 87
Helsinn Healthcare S.A., H1 2013 88
Wellstat Therapeutics Corporation, H1 2013 89
Ventria Bioscience, H1 2013 90
PledPharma AB, H1 2013 91
Tranzyme Pharma, Inc., H1 2013 92
Indus Biotech Private Limited, H1 2013 93
Synageva BioPharma Corp., H1 2013 94
Phage Biotechnology Corporation, H1 2013 95
Inimex Pharmaceuticals, Inc., H1 2013 96
Bolder Biotechnology, Inc., H1 2013 97
Shin Nippon Biomedical Laboratories, Ltd., H1 2013 98
Welichem Biotech Inc., H1 2013 99
Sound Pharmaceuticals, Inc., H1 2013 100
SpePharm Holding B.V., H1 2013 101
Biothera, H1 2013 102
Avesthagen Limited, H1 2013 103
Spinifex Pharmaceuticals Pty Limited, H1 2013 104
Tosk, Inc., H1 2013 105
Almac Discovery Ltd., H1 2013 106
Pfenex Inc., H1 2013 107
Mycenax Biotech Inc., H1 2013 108
Therapure Biopharma Inc., H1 2013 109
Eurofarma, H1 2013 110
Neumedicines Inc., H1 2013 111
Applied Protein Sciences, LLC, H1 2013 112
Acacia Pharma Ltd., H1 2013 113
Advancell, H1 2013 114
Assessment by Monotherapy Products, H1 2013 115
Assessment by Combination Products, H1 2013 116
Assessment by Stage and Route of Administration, H1 2013 118
Assessment by Stage and Molecule Type, H1 2013 121
Chemotherapy Effects Therapeutics - Drug Profile Updates 254
Chemotherapy Effects Therapeutics - Discontinued Products 290
Chemotherapy Effects Therapeutics - Dormant Products 291
Chemotherapy Effects Therapeutics - Dormant Products (Contd..1) 292
Chemotherapy Effects Therapeutics - Dormant Products (Contd..2) 293
Chemotherapy Effects Therapeutics - Dormant Products (Contd..3) 294



List of Figures

Number of Products under Development for Chemotherapy Effects, H1 2013 20
Products under Development for Chemotherapy Effects - Comparative Analysis, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Investigation by Universities/Institutes, H1 2013 29
Late Stage Products, H1 2013 31
Mid Clinical Stage Products, H1 2013 32
Early Clinical Stage Products, H1 2013 33
Discovery and Pre-Clinical Stage Products, H1 2013 34
Assessment by Monotherapy Products, H1 2013 115
Assessment by Combination Products, H1 2013 116
Assessment by Route of Administration, H1 2013 117
Assessment by Stage and Route of Administration, H1 2013 118
Assessment by Molecule Type, H1 2013 119
Assessment by Stage and Molecule Type, H1 2013 120

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.